Drug Repurposing in Parkinson's Disease

被引：40

作者：

Athauda, Dilan ^{[1
,2
]}

Foltynie, Thomas ^{[1
,2
]}

机构：

[1] UCL Inst Neurol, Dept Clin & Movement Neurosci, Queen Sq, London, England

[2] Natl Hosp Neurol & Neurosurg, Queen Sq, London, England

来源：

CNS DRUGS | 2018年 / 32卷 / 08期

关键词：

CALCIUM-CHANNEL BLOCKERS; GLUCAGON-LIKE PEPTIDE-1; MPTP MOUSE MODEL; ALPHA-SYNUCLEIN; DOPAMINERGIC-NEURONS; URSODEOXYCHOLIC ACID; PLASMA URATE; TAUROURSODEOXYCHOLIC ACID; MOLECULAR-MECHANISMS; CEREBROSPINAL-FLUID;

D O I：

10.1007/s40263-018-0548-y

中图分类号：

R74 [神经病学与精神病学];

学科分类号：

100204 [神经病学];

摘要：

The development of an intervention to slow or halt disease progression remains the greatest unmet therapeutic need in Parkinson's disease. Given the number of failures of various novel interventions in disease-modifying clinical trials in combination with the ever-increasing costs and lengthy processes for drug development, attention is being turned to utilizing existing compounds approved for other indications as novel treatments in Parkinson's disease. Advances in rational and systemic drug repurposing have identified a number of drugs with potential benefits for Parkinson's disease pathology and offer a potentially quicker route to drug discovery. Here, we review the safety and potential efficacy of the most promising candidates repurposed as potential disease-modifying treatments for Parkinson's disease in the advanced stages of clinical testing.

引用

页码：747 / 761

页数：15

共 162 条

[1]

Ursodeoxycholic Acid Ameliorates Apoptotic Cascade in the Rotenone Model of Parkinson's Disease: Modulation of Mitochondrial Perturbations [J].

Abdelkader, Noha F. ;

Safar, Marwa M. ;

Salem, Hesham A. .

MOLECULAR NEUROBIOLOGY, 2016, 53 (02) :810-817

[2]

A New Glucocerebrosidase Chaperone Reduces α-Synuclein and Glycolipid Levels in iPSC-Derived Dopaminergic Neurons from Patients with Gaucher Disease and Parkinsonism [J].

Aflaki, Elma ;

Borger, Daniel K. ;

Moaven, Nima ;

Stubblefield, Barbara K. ;

Rogers, Steven A. ;

Patnaik, Samarjit ;

Schoenen, Frank J. ;

Westbroek, Wendy ;

Zheng, Wei ;

Sullivan, Patricia ;

Fujiwara, Hideji ;

Sidhu, Rohini ;

Khaliq, Zayd M. ;

Lopez, Grisel J. ;

Goldstein, David S. ;

Ory, Daniel S. ;

Marugan, Juan ;

Sidransky, Ellen .

JOURNAL OF NEUROSCIENCE, 2016, 36 (28) :7441-7452

[3]

Gout and risk of Parkinson disease -: A prospective study [J].

Alonso, Alvaro ;

Garcia Rodriguez, Luis A. ;

Logroscino, Giancarlo ;

Hernan, Miguel A. .

NEUROLOGY, 2007, 69 (17) :1696-1700

[4]

Ambroxol-induced rescue of defective glucocerebrosidase is associated with increased LIMP-2 and saposin C levels in GBA1 mutant Parkinson's disease cells [J].

Ambrosi, Giulia ;

Ghezzi, Cristina ;

Zangaglia, Roberta ;

Levandis, Giovanna ;

Pacchetti, Claudio ;

Blandini, Fabio .

NEUROBIOLOGY OF DISEASE, 2015, 82 :235-242

[5]

Urate as a Predictor of the Rate of Clinical Decline in Parkinson Disease [J].

Ascherio, Alberto ;

LeWitt, Peter A. ;

Xu, Kui ;

Eberly, Shirley ;

Watts, Arthur ;

Matson, Wayne R. ;

Marras, Connie ;

Kieburtz, Karl ;

Rudolph, Alice ;

Bogdanov, Mikhail B. ;

Schwid, Steven R. ;

Tennis, Marsha ;

Tanner, Caroline M. ;

Beal, M. Flint ;

Lang, Anthony E. ;

Oakes, David ;

Fahn, Stanley ;

Shoulson, Ira ;

Schwarzschild, Michael A. .

ARCHIVES OF NEUROLOGY, 2009, 66 (12) :1460-1468

[6]

Drug repositioning: Identifying and developing new uses for existing drugs [J].

Ashburn, TT ;

Thor, KB .

NATURE REVIEWS DRUG DISCOVERY, 2004, 3 (08) :673-683

[7]

Insulin resistance and Parkinson's disease: A new target for disease modification? [J].

Athauda, D. ;

Foltynie, T. .

PROGRESS IN NEUROBIOLOGY, 2016, 145 :98-120

[8]

What Effects Might Exenatide have on Non-Motor Symptoms in Parkinson's Disease: A Post Hoc Analysis [J].

Athauda, Dilan ;

Maclagan, Kate ;

Budnik, Natalia ;

Zampedri, Luca ;

Hibbert, Steve ;

Skene, Simon S. ;

Chowdhury, Kashfia ;

Aviles-Olmos, Iciar ;

Limousin, Patricia ;

Foltynie, Thomas .

JOURNAL OF PARKINSONS DISEASE, 2018, 8 (02) :247-258

[9]

Exenatide once weekly versus placebo in Parkinson's disease: a randomised, double-blind, placebo-controlled trial [J].

Athauda, Dilan ;

Maclagan, Kate ;

Skene, Simon S. ;

Bajwa-Joseph, Martha ;

Letchford, Dawn ;

Chowdhury, Kashfia ;

Hibbert, Steve ;

Budnik, Natalia ;

Zampedri, Luca ;

Dickson, John ;

Li, Yazhou ;

Aviles-Olmos, Iciar ;

Warner, Thomas T. ;

Limousin, Patricia ;

Lees, Andrew J. ;

Greig, Nigel H. ;

Tebbs, Susan ;

Foltynie, Thomas .

LANCET, 2017, 390 (10103) :1664-1675

[10]

The glucagon-like peptide 1 (GLP) receptor as a therapeutic target in Parkinson's disease: mechanisms of action [J].

Athauda, Dilan ;

Foltynie, Thomas .

DRUG DISCOVERY TODAY, 2016, 21 (05) :802-818

← 1 2 3 4 5 6 7 8 9 10 →